🇺🇸 RMC-4630 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 11

Most-reported reactions

1. Hypokalaemia — 2 reports (18.18%)
2. Acute Hepatic Failure — 1 report (9.09%)
3. Acute Kidney Injury — 1 report (9.09%)
4. Acute Respiratory Failure — 1 report (9.09%)
5. Anaemia — 1 report (9.09%)
6. Cardiac Arrest — 1 report (9.09%)
7. Cholelithiasis — 1 report (9.09%)
8. Cholestasis — 1 report (9.09%)
9. Chronic Obstructive Pulmonary Disease — 1 report (9.09%)
10. Colitis — 1 report (9.09%)

Source database →

Frequently asked questions

Is RMC-4630 approved in United States?

RMC-4630 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for RMC-4630 in United States?

Revolution Medicines, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.